zilucoplan (Zilbrysq)

following a full submission assessed under the orphan equivalent medicine process

zilucoplan (Zilbrysq®) is not recommended for use within NHSScotland.

Indication under review: as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

In a double-blind phase III study, the addition of zilucoplan to standard therapy was associated with a statistically significant reduction in patient-reported myasthenia gravis symptoms and their effects on daily activities compared with placebo in patients with gMG who were AChR antibody positive.

The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.